Janney Montgomery Scott
OCUL icon

Janney Montgomery Scott’s Ocular Therapeutix OCUL Stock Holding History

Janney Montgomery Scott’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,000
Closed -$102K – 1852
2017
Q2 		$102K Sell
11,000
-900
-8% -$8.71K ﹤0.01% 1695
2017
Q1 		$110K Buy
+11,900
New +$99.1K ﹤0.01% 1684

Other funds holding OCUL

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janney Montgomery Scott's OCUL Position: Q3 2017 in Review

Janney Montgomery Scott sold out of Ocular Therapeutix (OCUL) in Q3 2017, closing a stake of 11,000 shares — an estimated $102K sold.

Janney Montgomery Scott first reported a position in OCUL in Q1 2017 and held it in 2 quarters. The position peaked at $110K in Q1 2017. 73 funds tracked by Wall St. Rank hold OCUL as of Q3 2017.

  • Janney Montgomery Scott reported no remaining Ocular Therapeutix position as of Q3 2017 after selling out during the quarter.
  • Janney Montgomery Scott sold 11,000 Ocular Therapeutix shares in Q3 2017, an estimated $102K.
  • Janney Montgomery Scott first reported a position in Ocular Therapeutix in Q1 2017 and held it in 2 quarters.
  • Janney Montgomery Scott's Ocular Therapeutix position peaked at $110K in Q1 2017.
  • 73 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2017.

Based on Janney Montgomery Scott's 13F filing for Q3 2017, filed 15 Nov 2017.